EA202193024A1 - Анти-cd19-терапия у пациентов с ограниченным числом естественных клеток-киллеров - Google Patents

Анти-cd19-терапия у пациентов с ограниченным числом естественных клеток-киллеров

Info

Publication number
EA202193024A1
EA202193024A1 EA202193024A EA202193024A EA202193024A1 EA 202193024 A1 EA202193024 A1 EA 202193024A1 EA 202193024 A EA202193024 A EA 202193024A EA 202193024 A EA202193024 A EA 202193024A EA 202193024 A1 EA202193024 A1 EA 202193024A1
Authority
EA
Eurasian Patent Office
Prior art keywords
patients
therapy
limited number
natural killer
killer cells
Prior art date
Application number
EA202193024A
Other languages
English (en)
Russian (ru)
Inventor
Кристиан Куффер
Гюнтер Фингерле-Роусон
Марк Виндерлих
Ян Энделль
Original Assignee
МорфоСис АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МорфоСис АГ filed Critical МорфоСис АГ
Publication of EA202193024A1 publication Critical patent/EA202193024A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Ecology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202193024A 2019-05-03 2020-05-04 Анти-cd19-терапия у пациентов с ограниченным числом естественных клеток-киллеров EA202193024A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19172495 2019-05-03
PCT/EP2020/062289 WO2020225196A1 (en) 2019-05-03 2020-05-04 Anti-cd19 therapy in patients having a limited number of nk cells

Publications (1)

Publication Number Publication Date
EA202193024A1 true EA202193024A1 (ru) 2022-02-09

Family

ID=66647010

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193024A EA202193024A1 (ru) 2019-05-03 2020-05-04 Анти-cd19-терапия у пациентов с ограниченным числом естественных клеток-киллеров

Country Status (15)

Country Link
US (1) US20220242952A1 (cg-RX-API-DMAC7.html)
EP (1) EP3962943A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022532519A (cg-RX-API-DMAC7.html)
KR (1) KR20220007087A (cg-RX-API-DMAC7.html)
CN (1) CN114072424A (cg-RX-API-DMAC7.html)
AU (1) AU2020267823A1 (cg-RX-API-DMAC7.html)
CA (1) CA3137664A1 (cg-RX-API-DMAC7.html)
EA (1) EA202193024A1 (cg-RX-API-DMAC7.html)
IL (1) IL287203A (cg-RX-API-DMAC7.html)
MA (1) MA55794A (cg-RX-API-DMAC7.html)
MX (1) MX2021013101A (cg-RX-API-DMAC7.html)
MY (1) MY209449A (cg-RX-API-DMAC7.html)
PH (1) PH12021552743A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111343TA (cg-RX-API-DMAC7.html)
WO (1) WO2020225196A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
ES2981046T3 (es) 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
SMT202100317T1 (it) 2016-06-27 2021-07-12 Morphosys Ag Formulazioni di anticorpi anti-cd19
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2021084062A1 (en) * 2019-10-31 2021-05-06 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗cd19抗体
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
ES2981046T3 (es) * 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes

Also Published As

Publication number Publication date
PH12021552743A1 (en) 2022-07-11
MA55794A (fr) 2022-03-09
CA3137664A1 (en) 2020-11-12
US20220242952A1 (en) 2022-08-04
CN114072424A (zh) 2022-02-18
EP3962943A1 (en) 2022-03-09
MY209449A (en) 2025-07-09
JP2026004466A (ja) 2026-01-14
WO2020225196A1 (en) 2020-11-12
IL287203A (en) 2021-12-01
SG11202111343TA (en) 2021-11-29
AU2020267823A1 (en) 2021-11-11
JP2022532519A (ja) 2022-07-15
MX2021013101A (es) 2022-01-04
KR20220007087A (ko) 2022-01-18

Similar Documents

Publication Publication Date Title
PH12021552743A1 (en) Anti-cd19 therapy in patients having a limited number of nk cells
EA202092243A1 (ru) Способы усиления персистенции адоптивно инфузированных т-клеток
PH12020551923A1 (en) Methods and compositions for treating cancer
Xu-Monette et al. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
MY209474A (en) Il-2 conjugates and methods of use to treat autoimmune diseases
ZA202100296B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
CY1126559T1 (el) Παραδειγμα θεραπειας για θεραπεια συνδυασμου anti-cd19 αντισωματος και βενετοκλαξης
MY194175A (en) Variant rnai
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
MY205041A (en) Variant rnai
BR112018072701A2 (pt) métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais
HK1248133A1 (zh) 治疗神经母细胞瘤的方法
PH12021551166A1 (en) Combination therapy of arms and natural killer cells
MA69251B1 (fr) Thérapie combinée antitumorale comprenant un anticorps anti-cd19 et des cellules t gamma delta
ZA202006077B (en) Human kynureninase enzymes and uses thereof
BR112023018621A2 (pt) Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii
PH12021551246A1 (en) Placenta-derived allogeneic car-t cells and uses thereof
MX2025004473A (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos
WO2020072519A8 (en) Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
ZA202306045B (en) Pulsed electric field treatment of biological cells
MX2020013103A (es) Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
EA201992875A1 (ru) T-клетки со сниженным поверхностным фукозилированием и способы их получения и применения
MX2024010925A (es) Uso de isatuximab en combinacion con otros agentes para el tratamiento del mieloma multiple
MX2022006715A (es) Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b.
MX2019013160A (es) Metodos de tratamiento selectivo del asma usando antagonistas de il-17.